Loading...

Aldeyra Therapeutics

DB:137
Snowflake Description

Flawless balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
137
DB
$224M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The last earnings update was 48 days ago. More info.


Add to Portfolio Compare Print
  • Aldeyra Therapeutics has significant price volatility in the past 3 months.
137 Share Price and Events
7 Day Returns
6.7%
DB:137
0.4%
DE Biotechs
0.8%
DE Market
1 Year Returns
22.2%
DB:137
-5.6%
DE Biotechs
-4.5%
DE Market
137 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Aldeyra Therapeutics (137) 6.7% -33.4% -3.2% 22.2% 32.6% -
DE Biotechs 0.4% 7.3% -6.5% -5.6% 51.9% 10.5%
DE Market 0.8% 6.9% 8.1% -4.5% 10.4% 13.9%
1 Year Return vs Industry and Market
  • 137 outperformed the Biotechs industry which returned -5.6% over the past year.
  • 137 outperformed the Market in Germany which returned -4.5% over the past year.
Price Volatility
137
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Aldeyra Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Aldeyra Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €7.175.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Aldeyra Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Aldeyra Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:137 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.79
NasdaqCM:ALDX Share Price ** NasdaqCM (2019-04-25) in USD $8.14
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.58x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Aldeyra Therapeutics.

DB:137 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:ALDX Share Price ÷ EPS (both in USD)

= 8.14 ÷ -1.79

-4.54x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Aldeyra Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Aldeyra Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Aldeyra Therapeutics's expected growth come at a high price?
Raw Data
DB:137 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.54x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
38.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.33x
Germany Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Aldeyra Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Aldeyra Therapeutics's assets?
Raw Data
DB:137 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $3.30
NasdaqCM:ALDX Share Price * NasdaqCM (2019-04-25) in USD $8.14
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.83x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:137 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:ALDX Share Price ÷ Book Value per Share (both in USD)

= 8.14 ÷ 3.30

2.47x

* Primary Listing of Aldeyra Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Aldeyra Therapeutics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Aldeyra Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Aldeyra Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Aldeyra Therapeutics expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
38.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Aldeyra Therapeutics expected to grow at an attractive rate?
  • Aldeyra Therapeutics's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Aldeyra Therapeutics's earnings growth is expected to exceed the Germany market average.
  • Unable to compare Aldeyra Therapeutics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:137 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:137 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 38.3%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:137 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:137 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 236 94 2
2022-12-31 149 61 58 3
2021-12-31 49 17 -44 4
2020-12-31 26 -27 -49 3
2019-12-31 0 -87 -49 4
DB:137 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -30 -39
2018-09-30 -27 -35
2018-06-30 -24 -29
2018-03-31 -23 -26
2017-12-31 -19 -22
2017-09-30 -18 -20
2017-06-30 -17 -20
2017-03-31 -15 -19
2016-12-31 -15 -19
2016-09-30 -14 -18
2016-06-30 -14 -17
2016-03-31 -12 -15

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Aldeyra Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Aldeyra Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:137 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Aldeyra Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:137 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31 2.33 2.33 2.33 1.00
2021-12-31 -0.56 0.57 -1.69 2.00
2020-12-31 -1.62 -1.20 -1.98 3.00
2019-12-31 -1.79 -1.61 -2.01 4.00
DB:137 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.79
2018-09-30 -1.77
2018-06-30 -1.58
2018-03-31 -1.48
2017-12-31 -1.40
2017-09-30 -1.40
2017-06-30 -1.47
2017-03-31 -1.52
2016-12-31 -1.65
2016-09-30 -1.73
2016-06-30 -1.71
2016-03-31 -1.59

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Aldeyra Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Aldeyra Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Aldeyra Therapeutics has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Aldeyra Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Aldeyra Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Aldeyra Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Aldeyra Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Aldeyra Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Aldeyra Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Aldeyra Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:137 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -38.89 9.88 29.82
2018-09-30 -35.21 8.83 26.82
2018-06-30 -29.39 7.24 22.48
2018-03-31 -25.65 6.35 19.53
2017-12-31 -22.34 6.19 16.30
2017-09-30 -20.04 5.89 14.20
2017-06-30 -19.83 5.81 14.05
2017-03-31 -18.82 5.79 13.03
2016-12-31 -18.70 5.52 13.18
2016-09-30 -18.40 5.54 12.84
2016-06-30 -16.99 5.41 11.53
2016-03-31 -14.92 4.90 9.95
2015-12-31 -12.09 4.41 7.57
2015-09-30 -10.18 4.20 5.87
2015-06-30 -8.82 3.71 4.98
2015-03-31 -11.70 3.73 4.40
2014-12-31 -9.57 3.56 3.71
2014-09-30 -6.33 3.39 2.70
2014-06-30 -3.45 3.12 2.17
2014-03-31 5.19 2.79 1.84
2013-12-31 1.11 2.13 1.54
2013-09-30 -37.31 1.32 1.24
2012-12-31 -39.13 0.64 0.47

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Aldeyra Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Aldeyra Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Aldeyra Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Aldeyra Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Aldeyra Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Aldeyra Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Aldeyra Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Aldeyra Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Aldeyra Therapeutics has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Aldeyra Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Aldeyra Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Aldeyra Therapeutics Company Filings, last reported 3 months ago.

DB:137 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 86.62 0.00 49.60
2018-09-30 28.60 1.35 24.14
2018-06-30 36.98 1.34 24.68
2018-03-31 36.00 1.34 38.94
2017-12-31 39.60 1.34 24.95
2017-09-30 45.90 1.33 47.91
2017-06-30 23.34 1.33 25.82
2017-03-31 28.00 1.32 31.21
2016-12-31 21.65 1.32 24.91
2016-09-30 25.67 1.31 28.88
2016-06-30 29.52 1.30 32.55
2016-03-31 20.53 1.30 23.03
2015-12-31 24.88 1.29 27.59
2015-09-30 28.70 1.28 30.62
2015-06-30 31.52 1.27 33.57
2015-03-31 13.83 1.26 15.72
2014-12-31 6.28 1.25 8.53
2014-09-30 8.26 1.24 10.14
2014-06-30 9.81 1.22 11.54
2014-03-31 0.62 1.36 2.15
2013-12-31 1.61 1.27 3.26
2013-09-30 2.22 0.35 2.76
2012-12-31 1.35 0.43 1.22
  • Aldeyra Therapeutics has no debt.
  • Aldeyra Therapeutics has no debt compared to 5 years ago when it was 79.4%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Aldeyra Therapeutics has sufficient cash runway for 1.6 years based on current free cash flow.
  • Aldeyra Therapeutics has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 33.6% each year.
X
Financial health checks
We assess Aldeyra Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Aldeyra Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Aldeyra Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Aldeyra Therapeutics dividends. Estimated to be 0% next year.
If you bought €2,000 of Aldeyra Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Aldeyra Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Aldeyra Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:137 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:137 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Aldeyra Therapeutics has not reported any payouts.
  • Unable to verify if Aldeyra Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Aldeyra Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Aldeyra Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Aldeyra Therapeutics's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Aldeyra Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Aldeyra Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Aldeyra Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Aldeyra Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Todd Brady
COMPENSATION $2,366,143
AGE 46
TENURE AS CEO 7.3 years
CEO Bio

Dr. Todd C. Brady, M.D., Ph.D., has been the Chief Executive Officer and President of Aldeyra Therapeutics, Inc. since January 2012. Dr. Brady is a Co-Founder of Phenome Sciences and serves as its Chief Executive Officer. He serves as a Senior Advisor at Solidus Investment Co., Ltd. He served as Principal Financial and Accounting Officer of Aldeyra Therapeutics, Inc. He was an Entrepreneur-In-Residence at Domain Associates, L.L.C since 2013. He joined Domain Associates in 2004 and served as Principal from 2004 to 2013. He served as an Executive Vice President of Strategic Development and Planning at Xanthus Pharmaceuticals. Dr. Brady served as the Head of Business Development and Medical Director at Aderis Pharmaceuticals. While at Xanthus and Aderis, he was a Medical Consultant on numerous pre-clinical programs and eleven clinical programs in Phases I through IV. He was an Associate of CB Health Ventures, L.L.C. and CB Healthcare II, LP. He was a Senior Associate at CB Health Ventures in Boston. He has been a Director of Spring Bank Pharmaceuticals, Inc. since July 28, 2016. Dr. Brady has been an Independent Director of Aldeyra Therapeutics, Inc. since 2005, Southeast BIO since November 2006 and Cantex Pharmaceuticals, Inc., since August 2006. He serves as a Director at Aldexa Pharmasceuticals, Asmacure Ltée, Neuron Systems, Inc., NovaDigm Therapeutics, Inc., Sebacia and CardioPolymers, Inc. He serves as Board Observer status at Orqis Medical, Regado Biosciences, Ruxton Pharmaceuticals, IntegenX Inc.,Cortria Corporation, Microchip Biotechnologies and Meritage Pharma, Inc. He served as a Director of Oncobiologics, Inc. from September 2014 to October 31, 2017. He served as Board Observer at Celator Pharmaceuticals, Inc. and Esperion Therapeutics, Inc. Dr. Brady has been a Director of Evoke Pharma, Inc., since June 2007. He served as an Board Observer at Helixis, Inc and Carticept Medical, Inc. He is on the grant review Board for the New Jersey Commission on Science and Technology, the venture capital Advisor to the New Jersey Biotechnology Council Board of Trustees, a Member of the Duke University Graduate School Board of Visitors, an Advisor to the Translational Science Institute at Wake Forest University and the University of Virgina Coulter Translational Research Advisory Board. He received an M.D. from Duke University Medical School in 1999 and a Ph.D. in Pathology and Integrated Toxicology from the Duke University Graduate School in 1998, while working on the pre-clinical development of catalytic anti-inflammatory compounds. He also received an A.B. in Philosophy and Psychology from Dartmouth College in 1993.

CEO Compensation
  • Todd's compensation has increased whilst company is loss making.
  • Todd's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Aldeyra Therapeutics management team in years:

2
Average Tenure
45.5
Average Age
  • The average tenure for the Aldeyra Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Todd Brady

TITLE
CEO, President & Director
COMPENSATION
$2M
AGE
46
TENURE
7.3 yrs

David Clark

TITLE
Chief Medical Officer
COMPENSATION
$1M
AGE
53
TENURE
3.3 yrs

Joshua Reed

TITLE
Chief Financial Officer
AGE
45
TENURE
0.8 yrs

Stephen Machatha

TITLE
Senior Vice President of Technical Operations
AGE
41
TENURE
0.3 yrs

Mary Taylor

TITLE
Senior Vice President of Regulatory Affairs
AGE
59
TENURE
3.2 yrs

Dave McMullin

TITLE
Chief Commercial Officer
AGE
43
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure and age of the Aldeyra Therapeutics board of directors in years:

5.8
Average Tenure
64
Average Age
  • The tenure for the Aldeyra Therapeutics board of directors is about average.
Board of Directors

Richard Douglas

TITLE
Chair of the Board
COMPENSATION
$132K
AGE
65
TENURE
1.8 yrs

Todd Brady

TITLE
CEO, President & Director
COMPENSATION
$2M
AGE
46
TENURE
14.3 yrs

Gary Phillips

TITLE
Director
COMPENSATION
$104K
AGE
52
TENURE
9.9 yrs

Martin Joyce

TITLE
Director
COMPENSATION
$117K
AGE
64
TENURE
5.5 yrs

Jesse Treu

TITLE
Director
COMPENSATION
$110K
AGE
71
TENURE
5.8 yrs

Ben Bronstein

TITLE
Director
COMPENSATION
$108K
AGE
68
TENURE
8.8 yrs

Neal Walker

TITLE
Director
COMPENSATION
$97K
AGE
48
TENURE
5.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
28. Mar 19 Sell Domain Associates, L.L.C. Company 26. Mar 19 26. Mar 19 -96,743 €8.87 €-857,903
X
Management checks
We assess Aldeyra Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Aldeyra Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company’s lead product candidate is reproxalap, an ophthalmic solution, which is in Phase IIb clinical trial for the treatment of dry eye diseases, as well as Phase III clinical trial for the treatment of allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson syndrome. Its portfolio also consists of ADX-1612, a small molecule heat shock protein 90 (Hsp90) inhibitor for the treatment of lymphoproliferative inflammatory diseases; and reactive aldehyde species that are pro-inflammatory (RASP) scavengers, such as ADX-629 for treating autoimmune diseases, as well as ADX-103 for the treatment of retinal diseases. In addition, the company develops ADX-2191, an intravitreal dihydrofolate reductase inhibitor for the prevention of proliferative vitreoretinopathy, a sight-threatening retinal disease; and ADX-1615, which inhibits Hsp90 for the treatment of various inflammatory diseases. Aldeyra Therapeutics, Inc. has a partnership with Janssen, a Johnson & Johnson company to develop RASP for systemic inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is headquartered in Lexington, Massachusetts.

Details
Name: Aldeyra Therapeutics, Inc.
137
Exchange: DB
Founded: 2004
$200,903,476
27,490,551
Website: http://www.aldeyra.com
Address: Aldeyra Therapeutics, Inc.
131 Hartwell Avenue,
Suite 320,
Lexington,
Massachusetts, 02421,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM ALDX Common Stock Nasdaq Capital Market US USD 02. May 2014
DB 137 Common Stock Deutsche Boerse AG DE EUR 02. May 2014
Number of employees
Current staff
Staff numbers
19
Aldeyra Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 22:24
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/04/02
Last earnings filing: 2019/03/08
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.